Literature DB >> 10051648

Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity.

A Bukreyev1, S S Whitehead, N Bukreyeva, B R Murphy, P L Collins.   

Abstract

Interferon gamma (IFN-gamma) has pleiotropic biological effects, including intrinsic antiviral activity as well as stimulation and regulation of immune responses. An infectious recombinant human respiratory syncytial virus (rRSV/mIFN-gamma) was constructed that encodes murine (m) IFN-gamma as a separate gene inserted into the G-F intergenic region. Cultured cells infected with rRSV/mIFN-gamma secreted 22 microg mIFN-gamma per 10(6) cells. The replication of rRSV/mIFN-gamma, but not that of a control chimeric rRSV containing the chloramphenicol acetyl transferase (CAT) gene as an additional gene, was 63- and 20-fold lower than that of wild-type (wt) RSV in the upper and lower respiratory tract, respectively, of mice. Thus, the attenuation of rRSV/mIFN-gamma in vivo could be attributed to the activity of mIFN-gamma and not to the presence of the additional gene per se. The mice were completely resistant to subsequent challenge with wt RSV. Despite its growth restriction, infection of mice with rRSV/mIFN-gamma induced a level of RSV-specific antibodies that, on day 56, was comparable to or greater than that induced by infection with wt RSV. Mice infected with rRSV/mIFN-gamma developed a high level of IFN-gamma mRNA and an increased amount of interleukin 12 p40 mRNA in their lungs, whereas other cytokine mRNAs tested were unchanged compared with those induced by wt RSV. Because attenuation of RSV typically is accompanied by a reduction in immunogenicity, expression of IFN-gamma by an rRSV represents a method of attenuation in which immunogenicity can be maintained rather than be reduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051648      PMCID: PMC26790          DOI: 10.1073/pnas.96.5.2367

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  Recombinant viruses as vaccines and immunological tools.

Authors:  M S Rolph; I A Ramshaw
Journal:  Curr Opin Immunol       Date:  1997-08       Impact factor: 7.486

2.  Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.

Authors:  M J Schnell; L Buonocore; E Kretzschmar; E Johnson; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus.

Authors:  T Hussell; L C Spender; A Georgiou; A O'Garra; P J Openshaw
Journal:  J Gen Virol       Date:  1996-10       Impact factor: 3.891

6.  Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression.

Authors:  C Flexner; A Hügin; B Moss
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

7.  Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses.

Authors:  K Karaca; J M Sharma; B J Winslow; D E Junker; S Reddy; M Cochran; J McMillen
Journal:  Vaccine       Date:  1998-10       Impact factor: 3.641

8.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.

Authors:  I A Ramshaw; M E Andrew; S M Phillips; D B Boyle; B E Coupar
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

9.  Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.

Authors:  B R Murphy; D W Alling; M H Snyder; E E Walsh; G A Prince; R M Chanock; V G Hemming; W J Rodriguez; H W Kim; B S Graham
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

10.  Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.

Authors:  G P Bembridge; J A Lopez; R Cook; J A Melero; G Taylor
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

View more
  19 in total

Review 1.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice.

Authors:  John A Ellis; Brittany V Martin; Cheryl Waldner; Kimberly D Dyer; Joseph B Domachowske; Helene F Rosenberg
Journal:  Vaccine       Date:  2006-10-12       Impact factor: 3.641

4.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.

Authors:  James A Harker; Debbie C P Lee; Yuko Yamaguchi; Belinda Wang; Alexander Bukreyev; Peter L Collins; John S Tregoning; Peter J M Openshaw
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

6.  Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.

Authors:  Liqun Zhang; Mark E Peeples; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines.

Authors:  A Bukreyev; S S Whitehead; C Prussin; B R Murphy; P L Collins
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 8.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

Authors:  Zhuhui Huang; Subbiah Elankumaran; Abdul S Yunus; Siba K Samal
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Virally delivered cytokines alter the immune response to future lung infections.

Authors:  James Harker; Alexander Bukreyev; Peter L Collins; Belinda Wang; Peter J M Openshaw; John S Tregoning
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.